Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Matrixyl vs Rigin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Matrixyl and Rigin share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Matrixyl has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Matrixyl's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Matrixyl

Cosmetic Clinical Studies

Rigin

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Matrixyl Rigin
Class Cosmetic signal peptide; collagen stimulator Cosmetic lipopeptide (anti-inflammatory)
Drug class Dermatologic Dermatologic
Mechanism Mimics procollagen I fragment; signals fibroblasts to produce collagen, elastin, GAGs Suppresses IL-6 secretion by fibroblasts; reduces inflammaging
Route Topical Topical
Half-life Topical Topical
Dosage (research) Topical 3-10% Topical 2-4%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 32 indexed (PubMed 15 · CT 0 · EPMC 17) 31 indexed (PubMed 15 · CT 0 · EPMC 16)
Availability Cosmetic Cosmetic
Reported risks Minimal (topical) Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Matrixyl or Rigin?

Matrixyl and Rigin share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Matrixyl has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Matrixyl's evidence base is currently denser.

What is the difference between Matrixyl and Rigin?

Matrixyl is classed as Cosmetic signal peptide; collagen stimulator; Rigin is classed as Cosmetic lipopeptide (anti-inflammatory). Reported mechanism: Matrixyl, Mimics procollagen I fragment; signals fibroblasts to produce collagen, elastin, GAGs; Rigin, Suppresses IL-6 secretion by fibroblasts; reduces inflammaging. Reported half-life: Matrixyl, Topical; Rigin, Topical. Routes in published studies: Matrixyl, Topical; Rigin, Topical.

Which has stronger evidence, Matrixyl or Rigin?

Matrixyl and Rigin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Matrixyl is graded Cosmetic Clinical Studies, with 6 cited sources on its reference page and 32 indexed studies. Rigin is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 31 indexed studies.

Which is more accessible, Matrixyl or Rigin?

Neither Matrixyl nor Rigin is an FDA-approved drug. Catalog status: Matrixyl, Cosmetic; Rigin, Cosmetic.

Are Matrixyl and Rigin ever combined?

Matrixyl and Rigin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…